**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a single centre retrospective study of 111 patients admitted to a hospital between 29 February 2020 to 6 April 2020 in Italy, a 71-year-old man [1](#Fn1){ref-type="fn"} was described, who died of bacterial superinfection following off-label use of tocilizumab for coronavirus disease-19 (COVID-19) pneumonia.

The man, who had COVID-19 pneumonia, received off-label treatment with a single infusion of IV tocilizumab 8 mg/kg. However, he was transferred to the ICU, wherein he developed bacterial superinfection \[*duration of treatment to reaction onset not stated*\]. He was placed on ventilator, but eventually died of bacterial superinfection.

Identifying patient details (age and sex) have been obtained through direct communication with the author on 14 July 2020. Previously, we had considered two patients having bacterial infection and bacterial superinfection one each. However, as per Author reply, it was found out that these both patients are same and hence, this case was created only for one patient.
